Growing Interest in Live Biotherapeutic Products Sparks Regulatory and Manufacturing Focus

The development of Live Biotherapeutic Products (LBPs) is gaining significant traction in the pharmaceutical sector, driven by clearer regulatory frameworks, scientific advancements, and increasing investor interest. As momentum builds, experts are urging stakeholders to adopt structured development strategies to address the complex manufacturing and quality demands of these novel therapeutics.

LBPs, defined as living organisms intended for disease treatment or prevention, are being propelled by regulatory clarity in markets such as the United States and European Union, improved oral delivery technologies, deeper insights into microbiome-linked diseases, and growing investment in scalable manufacturing methods.

A newly published whitepaper offers critical insights into the development pipeline of LBPs, particularly focusing on manufacturing processes and nonclinical evaluation. According to the report, chemistry, manufacturing, and controls play a pivotal role in ensuring the quality and safety of LBPs. However, developers face unique challenges not typically seen with conventional drugs, such as scale-up complexity, batch variability, and inconsistent strain performance.

Nonclinical evaluation, required before LBPs can be administered to humans, presents further hurdles. Unlike standard pharmaceuticals, LBPs often demand individualized assessment protocols, including safety, efficacy, and bacterial translocation analyses, which vary based on the strain and intended use.

With global interest and investment in microbiome-based therapies on the rise, the whitepaper underscores the importance of understanding the specialized pathways required for successful LBP development. It positions itself as a vital tool for biopharma companies seeking to navigate the intricacies of LBP regulation, mitigate developmental risks, and streamline time to market.

Download the full whitepaper from Novotech here.